|
1
|
Deręgowska J: Women with breast cancer in
the network of social support-a quantitative context. Nowiny
Lekarskie. 81:203–213. 2012.
|
|
2
|
Wang X, Tang S, Le SY, Lu R, Rader JS,
Meyers C and Zheng ZM: Aberrant expression of oncogenic and
tumor-suppressive MicroRNAs in cervical cancer is required for
cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ibeanu OA: Molecular pathogenesis of
cervical cancer. Cancer Biol Ther. 11:295–306. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Asih TS, Lenhart S, Wise S, Aryati L,
Adi-Kusumo F, Hardianti Ms and Forde J: The dynamics of Hpv
infection and cervical cancer cells. Bull Math Biol. 78:4–20. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiménez-Wences H, Peralta-Zaragoza O and
Fernández-Tilapa G: Human papilloma virus, DNA methylation and
microRNA expression in cervical cancer (Review). Oncol Rep.
31:2467–2476. 2014.PubMed/NCBI
|
|
7
|
Faridi R, Zahra A, Khan K and Idrees M:
Oncogenic potential of Human Papillomavirus (HPV) and its relation
with cervical cancer. Virol J. 8:2692011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fang J, Zhang H and Jin S: Epigenetics and
cervical cancer: From pathogenesis to therapy. Tumour Biol.
35:5083–5093. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang X, Zhang L, Tian C, Yang L and Wang
Z: Genetic variants and risk of cervical cancer: Epidemiological
evidence, meta-analysis and research review. BJOG. 121:664–674.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li D, Guo B, Wu H, Tan L and Lu Q: TET
family of dioxygenases: crucial roles and underlying mechanisms.
Cytogenet Genome Res. 146:171–180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abdel-Wahab O, Mullally A, Hedvat C,
Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara
O, Bhat R, et al: Genetic characterization of TET1, TET2 and TET3
alterations in myeloid malignancies. Blood. 114:144–147. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ito S, D'Alessio AC, Taranova OV, Hong K,
Sowers LC and Zhang Y: Role of tet proteins in 5mC to 5hmC
conversion, ES-cell self-renewal and inner cell mass specification.
Nature. 466:1129–1133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rawłuszko-Wieczorek AA, Siera A, Horbacka
K, Horst N, Krokowicz P and Jagodziński PP: Clinical significance
of DNA methylation mRNA levels of TET family members in colorectal
cancer. J Cancer Res Clin Oncol. 141:1379–1392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rawłuszko-Wieczorek AA, Siera A and
Jagodziński PP: TET proteins in cancer: Current ‘state of the art’.
Crit Rev Oncol Hematol. 96:425–436. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saavedra KP, Brebi PM and Roa JC:
Epigenetic alterations in preneoplastic and neoplastic lesions of
the cervix. Clin Epigenetics. 4:132012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Głowacki S and Błasiak J: Role of
5-hydroxymethylcytosine and TET proteins in epigenetic regulation
of gene expression. Postepy Biochem. 59:64–69. 2013.(In Polish).
PubMed/NCBI
|
|
17
|
Frycz BA, Murawa D, Borejsza-Wysocki M,
Marciniak R, Murawa P, Drews M, Kołodziejczak A, Tomela K and
Jagodziński PP: Decreased expression of ten-eleven translocation 1
protein is associated with some clinicopathological features in
gastric cancer. Biomed Pharmacother. 68:209–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kudo Y, Tateishi K, Yamamoto K, Yamamoto
S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H and Koike K:
Loss of 5-hydroxymethylcytosine is accompanied with malignant
cellular transformation. Cancer Sci. 103:670–676. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hsu CH, Peng KL, Kang ML, Chen YR, Yang
YC, Tsai CH, Chu CS, Jeng YM, Chen YT, Lin FM, et al: TET1
suppresses cancer invasion by activating the tissue inhibitors of
metalloproteinases. Cell Rep. 2:568–579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu
J, Xu ZD, Zhu HG, Ling ZQ, Ye D, et al: Tumor development is
associated with decrease of TET gene expression and
5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Müller T, Gessi M, Waha A, Isselstein LJ,
Luxen D, Freihoff D, Freihoff J, Becker A, Simon M, Hammes J, et
al: Nuclear exclusion of TET1 is associated with loss of
5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am J Pathol.
181:675–683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu C, Liu L, Chen X, Shen J, Shan J, Xu
Y, Yang Z, Wu L, Xia F, Bie P, et al: Decrease of
5-hydroxymethylcytosine is associated with progression of
hepatocellular carcinoma through downregulation of TET1. PLoS One.
8:e628282013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Afanas'ev I: Mechanisms of superoxide
signaling in epigenetic processes: Relation to aging and cancer.
Aging Dis. 6:216–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fan M, He X and Xu X: Restored expression
levels of TET1 decrease the proliferation and migration of renal
carcinoma cells. Mol Med Rep. 12:4837–4842. 2015.PubMed/NCBI
|
|
25
|
Tahiliani M, Koh KP, Shen Y, Pastor WA,
Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L and
Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in
mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guz J, Jurgowiak M and Oliński R:
Oxidation and deamination of nucleobases as an epigenetic tool.
Postepy Hig Med Dosw (Online). 66:275–286. 2012.(In Polish).
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Du C, Kurabe N, Matsushima Y, Suzuki M,
Kahyo T, Ohnishi I, Tanioka F, Tajima S, Goto M, Yamada H, et al:
Robust quantitative assessments of cytosine modifications and
changes in the expressions of related enzymes in gastric cancer.
Gastric Cancer. 18:516–525. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Böcker W: WHO classification of breast
tumors and tumors of the female genital organs: Pathology and
genetics. Verh Dtsch Ges Pathol. 86:116–119. 2002.(In German).
PubMed/NCBI
|
|
29
|
Chomczynski P and Sacchi N: Single-step
method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem.
162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q,
Ding J, Jia Y, Chen Z, Li L, et al: Tet-mediated formation of
5-carboxylcytosine and its excision by TDG in mammalian DNA.
Science. 333:1303–1307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu L, Mao SQ, Ray C, Zhang Y, Bell FT, Ng
SF, Xu GL and Li X: Differential regulation of genomic imprinting
by TET proteins in embryonic stem cells. Stem Cell Res. 15:435–443.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
An J, González-Avalos E, Chawla A, Jeong
M, López-Moyado IF, Li W, Goodell MA, Chavez L, Ko M and Rao A:
Acute loss of TET function results in aggressive myeloid cancer in
mice. Nat Commun. 6:100712015. View Article : Google Scholar : PubMed/NCBI
|
